Mental health · Texas
Mental health studies in Texas
127 studies have at least one recruiting site in Texas. Mental health research includes studies of depression, anxiety, PTSD, bipolar disorder, schizophrenia and ADHD, testing medicines, devices and talk therapies.
127 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
ALTO-100 in Bipolar Disorder With Depression (BD-D)
Alto Neuroscience
- Location
- Austin, TX + 38 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Austin, TX + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Draig Therapeutics Ltd
- Location
- Austin, TX + 18 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Eli Lilly and Company
- Location
- McKinney, TX + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of Brenipatide in Adult Participants With Schizophrenia
Eli Lilly and Company
- Location
- DeSoto, TX + 31 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Alkermes, Inc.
- Location
- Austin, TX + 17 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- Beaumont, TX + 28 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Dallas, TX + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Garland, TX + 12 other US sites
- Eligibility basics
- Ages 13–17
- Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
Fin-Ceramica Faenza Spa
- Location
- Rockwall, TX + 7 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Plano, TX + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals Inc.
- Location
- Houston, TX + 23 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company
- Location
- DeSoto, TX + 31 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Dallas, TX + 33 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Austin, TX + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Cypress, TX + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Cypress, TX + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Cypress, TX + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 2
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
Neurocrine Biosciences
- Location
- Austin, TX + 10 other US sites
- Eligibility basics
- Ages 18–65
- Recruiting
SAINT in Postpartum Depression (PPD)
Magnus Medical
- Location
- Austin, TX + 3 other US sites
- Eligibility basics
- Ages 18–45 · Women only
- RecruitingPhase 1
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
Janssen Research & Development, LLC
- Location
- Austin, TX + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Richardson, TX + 6 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will joining affect my current treatment?
Some studies require changes to medicines, which the study team manages; others add to your usual care. Talk to your own clinician before making any change.